The new PCE member Dutch Pancreatic Cancer is a member of the European Consortium of Minimally Invasive Pancreatic Surgery (E-MIPS).
E-MIPS has recently organized the DIPLOMA trial, which is coordinated by the AMC Amsterdam and University Hospital Southampton.The primary aim of the E-MIPS is to perform a pan-European randomized controlled trial of minimally invasive (either laparoscopic or robot-assisted) versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) in the pancreatic body or tail, with the aim to enhance patient’s recovery and lessen the impact of surgery without compromising oncological outcomes. In total 35 centers from 11 countries and 258 patients (129 minimally invasive and 129 open) are expected to participate in this trial.
Pancreatic Cancer Europe strongly supports high quality clinical trials conducted on pancreatic cancer, which are more than needed to improve outcomes and processes throughout the treatment pathway.
More information about the E-MIPS and DIPLOMA trial on their website: e-mips.org/diploma.
Pancreatic cancer has one of the worst prognoses, with a five-year survival rate of 9 percent, because of the lack of telltale symptoms or non-invasive screening tools to catch a tumor before it spreads.
University of Washington researchers have developed the BiliScreen app, which allow people to easily screen a susspected pancreatic cancer and other diseases - by snapping a smartphone selfie. BiliScreen uses a smartphone camera, computer vision algorithms and machine learning tools to detect increased bilirubin levels in a person's sclera, or the white part of the eye.
Indeed, one of the earliest symptoms of pancreatic cancer, as well as other diseases, is jaundice, a yellow discoloration of the skin and eyes caused by a buildup of bilirubin in the blood. So the ability to detect signs of jaundice when bilirubin levels are minimally elevated - but before they're visible to the naked eye - could enable an entirely new screening program for at-risk individuals.
In an initial clinical study of 70 people, the BiliScreen app correctly identified cases of concern 89.7% of the time, compared to the blood test currently used.
In contrast with others methods of screening, BiliScreen does not require access to a health care professional.
This app is a very interesting illustration of digital preventing tools, easy-to-use, and non-invasive, that could be efficient to determine whether someone ought to consult a doctor for further testing.
This new app was presented on the 13 of September at Ubicomp 2017, the Association for Computing Machinery's International Joint Conference on Pervasive and Ubiquitous Computing.
“On Wednesday 12th April 2017, EUPancreas (COST Action) and Pancreatic Cancer Europe gathered key pancreatic cancer research experts, clinicians, private domain representatives, health policy makers, and patient advocates during a meeting in Brussels.
This very first “Multistakeholder Brainstorming meeting” was organized around the belief that researchers, clinicians, patient representatives, pharma and biotech companies, policy makers, European institutions, in a joint collaboration, have a fundamental role to play in pancreatic cancer research.
Following an initiative from our Board Member, Dr. Nuria Malats, the exchanges aimed to propose concrete solutions in favour of research on pancreatic cancer in Europe. Indeed, we think it is time for EU institutions, Members of the European Parliament and national ministries to trigger real change in research, to further improve patient outcomes and survival rates.
The result of the exchanges are precise priorities for research on pancreatic cancer, that will be sent to European policy makers.
Please find here the minutes of the discussions and the list of participants. Please do not hesitate to contact the secretariat if you have any question or need more information.
Pancreatic Cancer Europe is proud to endorse ESMO World Congress on Gastrointestinal Cancer 2017. The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field – encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours. ESMO GI will take place in Barcelona, Spain – from the 28 June to the 1st of July 2017.
More information on their website www.worldgicancer.com/WCGI/index.asp
We are very delighted to announce you that Pancreatic Cancer Europe has a new sponsor!
Indeed, Mylan has joined us into our effort to raise awareness about pancreatic cancer.
Three years after its creation PCE has now three sponsors, thanks to the continuous effort of PCE Members in building the Platform ant its recognition. Thanks to the participation of this third sponsor PCE will certainly be able to run its action plan successfully and strive to improve proritization and knowledge of the disease for patients all over Europe. Thank you very much to Mylan.
Pancreatic cancer will this year become the third biggest cancer killer in the EU, yet awareness of the disease remains worryingly low. PCE Board Member, Matthias Löhr, on behalf of United European Gastroenterology (UEG-, has been interviewed by Portals for Horizon 2020 to highlight what needs to be done for Pancreatic Cancer.
You can find the full interview here
On 15 November, the members of Pancreatic Cancer Europe gathered in Brussels for their General Assembly meeting. At this occasion, members reviewed the 2016 action plan of PCE, and discussed and agreed on their priorities for 2017. The new action plan of PCE will be made available soon on the website.
To mark World Pancreatic Cancer Day 2016, Pancreatic Cancer Europe organised an awareness event in the European Parliament, hosted by Mr Pavel Poc MEP, under the auspices of the Slovak Presidency in the Council of the European Union.
Moderated by Jonathan Dimbleby, the event gathered key speakers:
- RNDr. Pavel Poc, Member of the European Parliament, Vice-chair of the ENVI Committee of the European Parliament and Vice-chair of the MEPs Against Cancer (MAC) group
- Ali Stunt, CEO and founder of Pancreatic Cancer Action, and founding board member of PCE
- Prof Alfredo Carrato, Professor & Director, Medical Oncology Department, Ramon y Cajal University Hospital, Alcala University, Madrid, Spain
- Prof Matthias Löhr, Karolinska Institutet / UEG
- Prof. Stanislav Špánik, Secretary of State of the Slovak Health Ministry
All Pancreatic Cancer Europe members would like to thank Mr Pavel Poc MEP and the Slovak Presidency of the Council of the EU for this great event and their contribution to raising awareness of pancreatic cancer in Europe.
The detailed minutes of the event will be available soon.
At the occasion of World Pancreatic Cancer Day 2016, Pancreatic Cancer Europe is organising jointly with Mr Pavel Poc MEP an awareness event in the European Parliament, held under the auspices of the Slovak Presidency in the Council of the European Union. The event will be moderated by Jonathan Dimbleby and will feature prominent speakers from, among others, UEG (United European Gastroenterology), ECPC (European Cancer Patient Coalition) and Pancreatic Cancer Action. The event will take place on 15 November, from 12.30 to 14.00 CET. In the morning, Pancreatic Cancer Europe will hold its General Assembly meeting in Brussels.
For more information, please contact us.
At the occasion of the 49th meeting of the European Pancreatic Club (EPC), the founding members of Pancreatic Cancer Europe*, newly established as a non-profit association, gathered in Liverpool on 6 July.
This meeting marked a new milestone in the life of Pancreatic Cancer Europe, and its continued work to improve the prioritisation of pancreatic cancer in public policies and the situation of pancreatic cancer patients across Europe.
The results of a large pan-European study by the European Study Group for Pancreatic Cancer (ESPAC) involving 732 patients has shown that the combination of gemcitabine plus capecitabine adjuvant therapy (following successful resection of the tumour) significantly improved survival.
We have seen a lot in the press recently about the advances in immunotherapy for many cancers and, in the case of melanoma, with extraordinary results.
We’ve not as yet seen this happen for pancreatic cancer which, so far, has proven difficult to treat with either conventional chemotherapy and/or novel immunotherapy. Some trials of immunotherapy (which targets the body’s immune system to fight the cancer) have failed and, it is believed one of the reasons for this is that pancreatic cancer tumours are cunning in the way they are able to manipulate the immune system to help their own progression.
Pancreatic cancer will become the 2nd leading cause of cancer-related death by the year 2030. There are different standards, therapies and settings in the European countries. Furthermore, there is no target-oriented treatment for patients with pancreatic cancer. “We treat all patients with Pancreatic cancer alike”, Professor Alfredo Carrato said, “but there are different groups and an urgent need to identify these groups by implementation of registries and biobanks”. Implementing efficient data collection and a European pancreatic cancer registry is the main objective of the Registries Work Stream of Pancreatic Cancer Europe, the European multi-stakeholder platform on pancreatic cancer.
On the occasion of the 2nd World Pancreatic Cancer Day, the European Multi-Stakeholder Platform on Pancreatic Cancer held its third face-to-face meeting in the European Parliament, in Brussels, on November 10th. More information to come soon!
Members of the platform also lead their activities at national level to celebrate the World Pancreatic Cancer Day. Visit the section Country information to find out more – click here ›